Cargando…

Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial

Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Tatsuya, Koyama, Yukari, Nishimura, Kosaku, Okiura, Aya, Takahashi, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658579/
https://www.ncbi.nlm.nih.gov/pubmed/36364740
http://dx.doi.org/10.3390/nu14214470
_version_ 1784829986185674752
author Abe, Tatsuya
Koyama, Yukari
Nishimura, Kosaku
Okiura, Aya
Takahashi, Toru
author_facet Abe, Tatsuya
Koyama, Yukari
Nishimura, Kosaku
Okiura, Aya
Takahashi, Toru
author_sort Abe, Tatsuya
collection PubMed
description Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this is a long-term effort and burden on patients. Thus, safer drugs and alternatives are needed. We previously found that consumption of tea prepared from fig (Ficus carica L.) leaves alleviated allergy and AD symptoms in cultured cells and animals. Therefore, here, we conducted a double-blind, randomized, controlled study in patients with mild AD to evaluate the safety and AD-relieving effects of prolonged consumption of fig leaf tea. Positive effects of fig leaf tea consumption were confirmed in 14 of 15 participants. Eczema Area and Severity Index values were significantly lowered in the fig leaf tea-treated group than in the placebo-treated group. The effect weakened 4 weeks after the end of the intervention, suggesting that continued intake of fig leaf tea was effective. Further assessments confirmed the safety of fig leaf tea consumption and revealed no variations that might pose a health hazard. Therefore, we postulate that fig leaf tea is a natural and safe therapeutic option for AD.
format Online
Article
Text
id pubmed-9658579
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96585792022-11-15 Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial Abe, Tatsuya Koyama, Yukari Nishimura, Kosaku Okiura, Aya Takahashi, Toru Nutrients Article Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this is a long-term effort and burden on patients. Thus, safer drugs and alternatives are needed. We previously found that consumption of tea prepared from fig (Ficus carica L.) leaves alleviated allergy and AD symptoms in cultured cells and animals. Therefore, here, we conducted a double-blind, randomized, controlled study in patients with mild AD to evaluate the safety and AD-relieving effects of prolonged consumption of fig leaf tea. Positive effects of fig leaf tea consumption were confirmed in 14 of 15 participants. Eczema Area and Severity Index values were significantly lowered in the fig leaf tea-treated group than in the placebo-treated group. The effect weakened 4 weeks after the end of the intervention, suggesting that continued intake of fig leaf tea was effective. Further assessments confirmed the safety of fig leaf tea consumption and revealed no variations that might pose a health hazard. Therefore, we postulate that fig leaf tea is a natural and safe therapeutic option for AD. MDPI 2022-10-25 /pmc/articles/PMC9658579/ /pubmed/36364740 http://dx.doi.org/10.3390/nu14214470 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abe, Tatsuya
Koyama, Yukari
Nishimura, Kosaku
Okiura, Aya
Takahashi, Toru
Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
title Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
title_full Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
title_fullStr Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
title_full_unstemmed Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
title_short Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
title_sort efficacy and safety of fig (ficus carica l.) leaf tea in adults with mild atopic dermatitis: a double-blind, randomized, placebo-controlled preliminary trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658579/
https://www.ncbi.nlm.nih.gov/pubmed/36364740
http://dx.doi.org/10.3390/nu14214470
work_keys_str_mv AT abetatsuya efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial
AT koyamayukari efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial
AT nishimurakosaku efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial
AT okiuraaya efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial
AT takahashitoru efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial